Abbvie Inc.

Augustine Osuma

Michael M Friedman

Noel S Wilson

Anil Vasudevan

Eric C Breinlinger

Justin D Dietrich

Kristine E Frank

Kenton L Longenecker

Kelly Mullen

Xiangdong Xu

David Ihle

George A Doherty

Bryan K Sorensen

Todd M Hansen

Michael Michaelides

Richard F Clark

Michael L Curtin

Marina Pliushchev

Robin R Frey

Michael Z Hoemann

Ramzi Farah Sweis

Howard Robin Heyman

Lu Wang

Andrew Burchat

Phil B Cox

David Andrew Kinsman

J Martin Herold

Andy Judd

Raymond Huntley

Huan-Qui Li

Ann Marie Rowley

Jennifer Van Camp

Stevan Wakefield Djuric

Arthur Gomtsyan

David A DeGoey

George S Sheppard

Jerome F Daanen

Sridhar Peddi

Arturo Perez-Medrano

William H Bunnelle

Jyoti R Patel

Robert G Schmidt

Lei Shi

Marc J Scanio

Michael Morytko

Maria A Argiriadi

Kevin Patrick Cusack

Grier A Wallace

Dominique Bonafoux

Heather M Davis

Zhi Wang

Gagandeep K Somal

Stacy A Van Epps

Philip Cox

Gloria Y LoSchiavo

Amanda W Dombrowski

The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions. 

Heterocyclic kinase inhibitors

The disclosure provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure are useful for treating immunological and oncological conditions.

Indazolones as modulators of TNF signaling

The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.

Tricyclic modulators of TNF signaling

The disclosure provides indazolone compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the disclosure may be useful for treating immunological and oncological conditions.

Indazolones as modulators of tnf signaling

The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Primary carboxamides as BTK inhibitors

Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.

NAMPT inhibitors

Disclosed herein are KCNQ potassium channels modulators of formula (I) wherein R, R, R, R, and Rare as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

Potassium channel modulators

Growing community of inventors

Lindenhurst, IL, United States of America

Augustine Osuma